AAV Manufacturing Insight: Understanding The Precipitates During Centrifugation in AAV Preparation

Adeno-associated virus (AAV) has emerged as a leading vector platform for in vivo gene therapy applications. During standard purification workflows, researchers frequently observe the formation of a white precipitate following centrifugation steps—particularly during polyethylene glycol (PEG) precipitation or ultracentrifugation. This phenomenon reflects critical biophysical properties of viral capsids and purification chemistry. Here, we examine the molecular basis of white precipitate formation, its composition, and strategies for optimization to enhance vector yield and purity.

Centrifugation serves as the primary separation mechanism throughout AAV downstream processing, operating on distinct principles depending on the purification stage. Differential centrifugation (typically 2,000–10,000 × g) removes cellular debris and large aggregates, whereas ultracentrifugation (≥100,000 × g) separates viral particles based on buoyant density using iodixanol or cesium chloride gradients.

The white precipitate most commonly appears during PEG precipitation, a concentration step where PEG 8000 (8–10% w/v) in the presence of high salt (2.5 M NaCl) induces hydrophobic exclusion of viral particles from solution. Following low-speed centrifugation (3,000–10,000 × g), viral particles aggregate into a dense, white pellet at the tube bottom, effectively concentrating the vector 10–100-fold from clarified supernatant.

The white precipitate represents a concentrated matrix of intact AAV capsids, partially assembled viral particles, and co-precipitating host cell proteins. AAV capsids—composed of 60 viral protein subunits (VP1, VP2, VP3) arranged in icosahedral symmetry—exhibit reduced solubility in high-molecular-weight PEG solutions due to their hydrophobic surface characteristics and isoelectric points (pI ~5.9–6.2).

During ultracentrifugation through density gradients, a distinct white band may appear at the 25%/40% iodixanol interface, representing aggregated empty capsids and protein contaminants that must be excluded during vector collection to ensure purity.

Multiple physicochemical factors govern white precipitate formation and characteristics:

Efficient handling of the white precipitate is crucial for maximizing vector recovery:

Resuspension Protocol: The PEG pellet adheres tenaciously to polypropylene surfaces. Gentle resuspension in digestion buffer (e.g., 50 mM Tris, 100 mM NaCl, 2 mM MgCl₂) using a P1000 pipette (avoiding serological pipettes that trap particles) is required. Vigorous vortexing should be avoided to prevent capsid disassembly and aeration.

Washing Procedures: Residual PEG and co-precipitated proteins can be removed through sequential washes with phosphate-buffered saline (PBS) containing 0.001% Pluronic F-68, a non-ionic surfactant that prevents vector loss via hydrophobic adhesion to plasticware.

Alternative Approaches: For serotypes prone to aggregation (e.g., AAV2, AAV5), aqueous two-phase partitioning (PEG/ammonium sulfate) may replace standard precipitation, offering superior separation of viral particles from soluble contaminants while maintaining high infectious titers.

Rather than merely representing process waste, the white precipitate serves as a valuable analytical specimen:

The formation of white precipitate during AAV centrifugation is an intrinsic feature of established purification workflows, particularly PEG-based concentration methods. Rather than indicating process failure, this phenomenon reflects the successful enrichment of viral vectors from complex biological matrices. By understanding the biophysical principles governing precipitation—hydrophobic interactions, ionic strength effects, and centrifugal parameters—researchers can optimize protocols to maximize vector recovery while minimizing protein contaminants. As gene therapy advances toward clinical applications, mastery of these fundamental purification phenomena remains essential for producing high-titer, clinical-grade AAV preparations suitable for in vivo therapeutic delivery.